Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StatePennsylvaniaIntroduced
HB 2226: An Act amending Title 40 (Insurance) of the Pennsylvania Consolidated Statutes, providing for prescription drug cost credits in health insurance; and imposing penalties.
Emily Kinkead
HB 2226 status: Introduced — Laid on the table (updated Sep 8, 2026).
Source
OpenStates
Confidence
Low
Analysis basis
OpenStates summary
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
63OUT OF 100
Score:63/100 civic fit
Risk:Moderate Risk
Impact:Moderate Impact 55/100
Constitutionality85%
Bipartisan50%
Public opinion80%
Bill summary
This bill aims to make prescription drugs cheaper for you. It would require insurance companies to pass any drug savings they receive on to their customers. If insurance companies don’t follow these rules, they will face fines. It is currently being discussed in the Pennsylvania House of Representatives.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Positive outlook
60%
Benefits
- Potential reduction in out-of-pocket prescription costs for consumers
- Requirement for insurance entities to pass through negotiated drug savings
- Economic relief for households with chronic medication needs
Risks
- Risk of insurance companies raising premiums to offset lost rebate revenue
- Operational compliance costs associated with rebate tracking systems
- Potential for insurance market volatility due to new mandates
Society
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
65%
Benefits
- Establishes a mandatory regulatory framework for drug savings
- Introduces explicit penalties for non-compliant insurance entities
- Enhances oversight of financial flows within the insurance sector
Risks
- Implementation depends on regulatory capacity to enforce penalties
- Risk of industry lobbying to weaken oversight requirements
- Ambiguity regarding how compliance is audited in practice
Public Health & Safety
Positive outlook
65%
Benefits
- Improved patient access to lower-cost essential medications
- Enhanced medication adherence by reducing financial barriers
- Lower fiscal stress on patients managing chronic health conditions
Risks
- Risk of insurance benefit designs shifting to accommodate costs
- Lack of guaranteed drug price reduction for uninsured populations
- Potential for narrowed formularies if insurers change strategies
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
OpenStates
Official bill text or data from OpenStates.
Confidence
Low
Information is limited or incomplete.
Analysis basis
OpenStates summary
Source used for this bill's analysis.
Source note
The bill may inadvertently trigger premium hikes if insurers re-balance costs in response to rebate pass-through mandates.
Analysis scope
Analysis is based on a summary abstract; full legislative text was not reviewed.
04
Where it stands
Official record- IntroducedCurrent
- CommitteeUpcoming
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.